enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 200 shares, a growth of 100.0% from the February 13th total of 100 shares. Based on an average trading volume of 9,200 shares, the short-interest ratio is presently 0.0 days.

enGene Price Performance

Shares of ENGNW stock traded up $0.05 during mid-day trading on Friday, hitting $0.69. The company had a trading volume of 5,402 shares, compared to its average volume of 14,181. The stock’s 50 day moving average price is $0.88 and its 200-day moving average price is $1.25. enGene has a 52-week low of $0.42 and a 52-week high of $6.50.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.